Stem Cell Therapy in Multiple Myeloma

1
Roshna P P
Roshna P P
2
Sreejith K
Sreejith K
1 Government Medical College

Send Message

To: Author

GJMR Volume 18 Issue C1

Article Fingerprint

ReserarchID

PS10H

Stem Cell Therapy in Multiple Myeloma Banner
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Multiple myeloma is a haematogical malignancy caused by abnormality of plasma cells characterized by (a) hypercalcemia, (b) renal insufficiency or failure, (c)bone pain and abnormal bone radiographs, (d) anemia and (e) a monoclonal protein in urine or serum or both. It begins in the form known as monoclonal gammopathy of undetermined significance(MGUS) and progresses to asymptomatic myeloma and then lastly to symptomatic myeloma. The three main domains in the understanding of pathophysiology are cytokines and cell signaling, bone Marrow Microenvironment and cell Cycle. Bifunctional alkylating agents like Melphalan and cyclophosphamide are considered as standard therapy for multiple myeloma. Patients who are chosen for stem cell transplantation can be treated with Lenalidomide, an immunomodulatory agent and an aminosustituted variant of Thalidomide. It is given along with dexamethasone. In stem cell therapy, the patients receive stem cells intravenously similar to the blood transfusion and this phase takes 1-5 hours. After entering the blood stream through a process called engraftment, the stem cell produce new WBCs, RBCs and platelets. The immune rejection of donor cells by the host immune system is a major drawback of transplantation. Stem cell therapy in multiple myeloma is very effective and should be opted as one among the best for both older patients and patients younger than 65 years.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

Roshna P P. 2018. \u201cStem Cell Therapy in Multiple Myeloma\u201d. Global Journal of Medical Research - C: Microbiology & Pathology GJMR-C Volume 18 (GJMR Volume 18 Issue C1): .

Download Citation

Article file ID not found.

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-C Classification: NLMC Code: WH 540
Version of record

v1.2

Issue date

July 30, 2018

Language

English

Experiance in AR

The methods for personal identification and authentication are no exception.

Read in 3D

The methods for personal identification and authentication are no exception.

Article Matrices
Total Views: 3041
Total Downloads: 1597
2026 Trends
Research Identity (RIN)
Related Research

Published Article

Multiple myeloma is a haematogical malignancy caused by abnormality of plasma cells characterized by (a) hypercalcemia, (b) renal insufficiency or failure, (c)bone pain and abnormal bone radiographs, (d) anemia and (e) a monoclonal protein in urine or serum or both. It begins in the form known as monoclonal gammopathy of undetermined significance(MGUS) and progresses to asymptomatic myeloma and then lastly to symptomatic myeloma. The three main domains in the understanding of pathophysiology are cytokines and cell signaling, bone Marrow Microenvironment and cell Cycle. Bifunctional alkylating agents like Melphalan and cyclophosphamide are considered as standard therapy for multiple myeloma. Patients who are chosen for stem cell transplantation can be treated with Lenalidomide, an immunomodulatory agent and an aminosustituted variant of Thalidomide. It is given along with dexamethasone. In stem cell therapy, the patients receive stem cells intravenously similar to the blood transfusion and this phase takes 1-5 hours. After entering the blood stream through a process called engraftment, the stem cell produce new WBCs, RBCs and platelets. The immune rejection of donor cells by the host immune system is a major drawback of transplantation. Stem cell therapy in multiple myeloma is very effective and should be opted as one among the best for both older patients and patients younger than 65 years.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]
×

This Page is Under Development

We are currently updating this article page for a better experience.

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Stem Cell Therapy in Multiple Myeloma

Roshna P P
Roshna P P Government Medical College
Sreejith K
Sreejith K

Research Journals